Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer
Isocitrate dehydrogenase (IDH) I and II mutations in gliomas cause an abnormal accumulation of 2-hydroxyglutarate (2-HG) in these tumor cells. These mutations have potential prognostic value in that knowledge of the mutation status can lead to improved surgical resection. Information on mutation status obtained by immunohistochemistry or genomic analysis is not available during surgery. We report a rapid extraction nanoelectrospray ionization (nESI) method of determining 2-HG. This should allow the determination of IDH mutation status to be performed intraoperatively, within minutes, using a miniature mass spectrometer. This study demonstrates that the combination of tandem mass spectrometry with low-resolution mass spectrometry allows this analysis to be performed with confidence.
Keywords2-Hydroxyglutarate Glutamate IDH mutation Tandem mass spectrometry Clinical analysis
The authors thank Dr. Mahua Dey, Dr. Charles Kulwin, Dr. James Miller, Dr. Troy Payner, Dr. Mitesh Shah, Dr. Scott Shapiro, and Dr. Aaron A. Cohen-Gadol at Goodman Campbell Brain and Spine (Indianapolis, IN) for providing tissue samples, and Dr. Eyas M. Hattab at the University of Louisville for pathology analysis. PURSPEC Technologies Inc. is acknowledged for providing the miniature mass spectrometry system and for technical support. Support from the Purdue University Center, Cancer Research Small Grants Program, is gratefully acknowledged.
This study received funding from Grant No. UL1TR002529 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; from the National Institute of Biomedical Imaging and Bioengineering, NIH Grant R21EB015722; from the National Institute of Allergy And Infectious Diseases, NIH Grant R01AI122298; and from the Purdue University Center for Cancer Research Small Grants Program.
Compliance with ethical standards
Banked tissue samples were obtained from the Methodist Research Institute Biorepository in Indianapolis in accordance with approved Institutional Review Board (IRB) protocols at Indiana University School of Medicine (IUSM) (IRB No. 1410015344). Tissues for bulk tissue analysis were prospectively obtained from human subjects undergoing tumor resection for suspected glioma at Indiana University Department of Neurosurgery, Goodman Campbell Brain and Spine Institute, after they had provided written informed consent to participate in the research study, following an IUSM IRB approved protocol (IRB No. 1410342262).
Conflict of interest
Zheng Ouyang is the founder of PURSPEC Technologies Inc.
- 1.Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology. 2017;19(suppl_5):v1–v88. https://doi.org/10.1093/neuonc/nox158.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMedGoogle Scholar
- 4.Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18. https://doi.org/10.1007/s00401-010-0781-z.CrossRefPubMedGoogle Scholar
- 7.Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–90. https://doi.org/10.1200/JCO.2013.49.3726.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 2014;16(1):81–91. https://doi.org/10.1093/neuonc/not159.CrossRefPubMedGoogle Scholar
- 11.Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4. https://doi.org/10.1126/scitranslmed.3002693.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol. 2012;107(1):197–205. https://doi.org/10.1007/s11060-011-0737-8.CrossRefGoogle Scholar
- 21.Pirro V, Alfaro CM, Jarmusch AK, Hattab EM, Cohen-Gadol AA, Cooks RG. Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. Proc Natl Acad Sci U S A. 2017;114(26):6700–5. https://doi.org/10.1073/pnas.1706459114. CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Margulis K, Chiou AS, Aasi SZ, Tibshirani RJ, Tang JY, Zare RN. Distinguishing malignant from benign microscopic skin lesions using desorption electrospray ionization mass spectrometry imaging. Proc Natl Acad Sci U S A. 2018;115(25):6347–52. https://doi.org/10.1073/pnas.1803733115.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Pirro V, Llor RS, Jarmusch AK, Alfaro CM, Cohen-Gadol AA, Hattab EM, et al. Analysis of human gliomas by swab touch spray-mass spectrometry: applications to intraoperative assessment of surgical margins and presence of oncometabolites. Analyst. 2017;142(21):4058–66. https://doi.org/10.1039/c7an01334e.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Zhang J, Rector J, Lin JQ, Young JH, Sans M, Katta N, et al. Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl Med. 2017;9(406). https://doi.org/10.1126/scitranslmed.aan3968.
- 32.Ouyang Z, Cooks RG. Miniature mass spectrometers. Annu Rev Anal Chem. 2009;2:187–214. https://doi.org/10.1146/annurev-anchem-060908-155229.CrossRefGoogle Scholar
- 34.Hendricks PI, Dalgleish JK, Shelley JT, Kirleis MA, McNicholas MT, Li L, et al. Autonomous in situ analysis and real-time chemical detection using a backpack miniature mass spectrometer: concept, instrumentation development, and performance. Anal Chem. 2014;86(6):2900–8. https://doi.org/10.1021/ac403765x. CrossRefPubMedGoogle Scholar
- 36.Alfaro CM, Pirro V, Keating MF, Hattab EM, Cooks RG, Cohen-Gadol AA. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry. J Neurosurg. 2019:1–8. https://doi.org/10.3171/2018.8.JNS181207.
- 37.Espy RD, Teunissen SF, Manicke NE, Ren Y, Ouyang Z, van Asten A, et al. Paper spray and extraction spray mass spectrometry for the direct and simultaneous quantification of eight drugs of abuse in whole blood. Anal Chem. 2014;86(15):7712–8. https://doi.org/10.1021/ac5016408. CrossRefPubMedGoogle Scholar
- 38.Ren Y, Liu J, Li L, McLuckey MN, Ouyang Z. Direct mass spectrometry analysis of untreated samples of ultralow amounts using extraction nano-electrospray. Anal Methods. 2013;5(23). https://doi.org/10.1039/C3AY41149D.
- 39.Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro-Oncology. 2016;18(11):1559–68. https://doi.org/10.1093/neuonc/now090. CrossRefPubMedPubMedCentralGoogle Scholar